GRI Bio Inc (GRI) Actualités

Form 8-K - Current report

GRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)

 Interim data and topline data readouts from Phase 2a biomarker study expected in Q2 2025 and Q3 2025...

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

GRI Bio Regains Compliance with Nasdaq’s Minimum Bid Price Rule

LA JOLLA, CA, March 11, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a...

Form 8-K - Current report

GRI Bio Announces Reverse Stock Split

GRI’s common stock is expected to begin trading on a post-split adjusted basis on February 24, 2025 LA JOLLA...

GRI Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

On-demand video webcast now available here  LA JOLLA, CA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc...

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form DEF 14A - Other definitive proxy statements

Form S-8 - Securities to be offered to employees in employee benefit plans

GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds

– Company committed to building a robust global patent estate across its innovative pipeline of NKT cell...